CRYOABLATION FOR PROSTATE CANCER:
WHOLE GLAND AND FOCAL TREATMENT
A complete guide to cryoablation for prostate cancer โ how whole-gland and focal cryoablation differ, what the evidence shows for each approach, who is the right candidate, and how to access specialist prostate cryoablation at centres in China and India.
analyticsAt a Glance
- check_circleWhole-gland cryoablation achieves PSA control rates comparable to radiotherapy for intermediate and high-risk localised prostate cancer
- check_circleFocal cryoablation (hemi-gland or quadrant) preserves potency and continence in the majority of carefully selected patients
- check_circleSalvage cryoablation after radiation failure โ cryoablation is the most established and evidence-based salvage modality
- check_circleCancerFax coordinates prostate cryoablation at specialist uro-oncology centres in China and India
Prostate Cryoablation โ Two Treatment Approaches
Prostate cryoablation is performed by inserting multiple cryoprobes through the perineum under transrectal ultrasound (TRUS) guidance into precise positions within the prostate gland. The probes are positioned based on the lesion location (defined by mpMRI and systematic biopsy mapping), and a planned freeze pattern destroys either the entire gland (whole-gland) or only the cancer-bearing tissue (focal).
โThe choice between whole-gland and focal cryoablation is fundamentally a trade-off between oncological certainty and functional preservation โ neither is universally superior.โ
Whole-Gland Cryoablation
Cryoprobes freeze the entire prostate, including the peripheral zone and anterior prostate, plus a margin into the periprostatic tissue. Intended to eliminate all prostate cancer cells โ multifocal and microscopic disease is treated alongside the dominant lesion. Equivalent oncological intent to radical prostatectomy or radiotherapy.
Focal Cryoablation (Hemi-gland / Quadrant)
Only the cancer-bearing lobe (hemi-gland) or sector (quadrant) is frozen โ the opposite lobe and the neurovascular bundles on the non-treated side are preserved. Requires highly accurate cancer localisation (mpMRI + targeted biopsy + MRI-US fusion) and acceptance that contralateral small-volume cancer may not be treated.',
Salvage Cryoablation โ After Radiation Failure
Cryoablation has the longest clinical history of any salvage modality after failed radiotherapy (external beam or brachytherapy). When PSA rises after radiation and biopsy confirms local recurrence, salvage cryoablation treats the prostate in its post-radiation state โ with documented long-term PSA control and well-characterised toxicity profile.
Cryoprobe Placement and TRUS Monitoring
Probes are inserted via a perineal template grid under real-time TRUS guidance โ the same grid used for systematic biopsy. The ice ball advance is monitored on TRUS, with thermocouple sensors confirming lethality within the gland and rectal safety. Urethral warming is used to protect the urethra from freeze injury.',
Prostate Cryoablation โ Oncological Outcomes
PSA control (biochemical no evidence of disease, bNED) and secondary treatment-free survival data from the primary evidence sources for whole-gland and salvage prostate cryoablation.
Whole-Gland Cryoablation โ 5-Year bNED by Risk Group (COLD Registry Data)
5-year biochemical no evidence of disease (bNED) rates stratified by NCCN risk group from the Cryo Online Data (COLD) registry โ the largest prostate cryoablation outcomes database. Source: Levy et al., BJU Int 2010 and updated analyses.
- 5-yr bNED: low-risk (whole-gland cryo)~85โ91%
- 5-yr bNED: intermediate-risk (whole-gland)~73โ82%
- 5-yr bNED: high-risk (whole-gland cryo)~66โ75%
Salvage Cryoablation After Radiation Failure โ 5-Year Outcomes
5-year bNED and recurrence-free survival in salvage cryoablation after prior external beam radiotherapy or brachytherapy failure. Source: Multiple retrospective series; Ismail et al., BJU Int; Pisters et al., J Urol.
- 5-yr bNED: salvage cryoablation (low pre-salvage PSA)~55โ70%
- 5-yr bNED: salvage cryoablation (high pre-salvage PSA)~30โ50%
Functional Outcomes โ Whole Gland vs Focal Cryoablation
Functional outcomes (continence, potency, lower urinary tract symptoms) differ significantly between whole-gland and focal approaches โ a critical consideration in treatment decision-making.
| Functional Outcome | Whole-Gland Cryoablation | Focal Cryoablation (Hemi-gland) | Notes |
|---|---|---|---|
| Urinary continence (pad-free) | ~93โ97% at 12 months | ~95โ98% at 12 months | Both approaches have good continence rates โ urethral warming protects sphincter |
| Erectile function preservation | ~20โ40% (bilateral NVB freeze) | ~50โ70% (ipsilateral NVB frozen; contralateral preserved) | Focal approach with contralateral NVB sparing significantly better |
| Lower urinary tract symptoms | Transient LUTS common weeks 2โ8; resolves ~90% | Less severe LUTS; faster resolution | Sloughed necrotic tissue through urethra is common; catheter 1โ2 weeks |
| Rectourethral fistula | <1% with modern third-generation systems | <0.5% | Rare but serious โ prevented by rectal temperature monitoring and warmer |
| Urethral stricture | ~2โ5% | ~1โ3% | Urethral warming reduces but does not eliminate risk |
When to Choose Whole-Gland vs Focal Cryoablation
The decision between whole-gland and focal cryoablation depends on oncological risk, cancer localisation certainty, and patient priorities for functional preservation.
Whole-Gland Cryoablation
- Intermediate and high-risk diseaseFor Gleason 7 (4+3) or above, multifocal or bilateral disease, whole-gland treatment provides oncological confidence that focal treatment cannot โ all cancer is treated regardless of contralateral microdeposits.
- Post-radiation salvageSalvage cryoablation is almost always whole-gland โ the entire previously irradiated prostate is treated to eliminate all residual viable cancer.
- Patient who prioritises oncological certainty over sexual functionWhole-gland cryoablation delivers the highest certainty of complete cancer treatment โ at the cost of higher bilateral neurovascular bundle freeze and erectile function loss.
Focal Cryoablation
- Unilateral low-to-intermediate-risk diseaseFor Gleason 3+4, clinically significant but localised to one lobe on mpMRI and targeted biopsy, focal hemi-gland cryoablation achieves disease control while sparing the contralateral side.
- Sexual function preservation is a priorityFocal cryoablation preserves the contralateral neurovascular bundle โ potency rates of 50โ70% are substantially better than whole-gland approaches.
- Requires precise cancer localisationFocal cryoablation is only appropriate when the dominant cancer is accurately localised by mpMRI and MRI-targeted biopsy โ non-targeted TRUS systematic biopsy alone is insufficient for focal treatment planning.
Prostate Cryoablation โ Key Numbers
The most clinically important outcome figures for prostate cryoablation across primary and salvage settings.
- ~85โ91%5-year bNED for low-risk prostate cancer (whole-gland cryoablation)Comparable to external beam radiotherapy and acceptable relative to radical prostatectomy for appropriately selected low-risk patients.
- 50โ70%Potency preservation with focal (hemi-gland) cryoablationSubstantially better than whole-gland cryoablation or radiotherapy โ the primary driver of focal treatment adoption in sexually active patients.
- <1%Rectourethral fistula rate with modern third-generation cryoablation systemsThe most feared complication of prostate cryoablation has become rare with modern systems, rectal temperature monitoring, and urethral warming.
More from the Cryoablation Resource Library
Explore the complete cryoablation library โ from the patient introduction and mechanism to kidney cancer outcomes.
Frequently Asked Questions: Prostate Cryoablation
My PSA has risen after radiotherapy. Is salvage cryoablation an option?
Yes โ salvage cryoablation after radiation failure is one of the most established indications for prostate cryoablation. It has the longest published follow-up data of any salvage modality for post-radiation prostate cancer recurrence. The key eligibility criteria for salvage cryoablation include: biopsy-confirmed local recurrence (not just PSA rise), absence of metastatic disease on imaging (PSMA PET ideally), pre-salvage PSA ideally below 10 ng/mL, and adequate life expectancy to benefit from local salvage. CancerFax reviews your radiation treatment history, PSA trajectory, and biopsy results to assess salvage cryoablation eligibility at specialist centres.
How is focal cryoablation different from HIFU for prostate cancer?
Both focal cryoablation and HIFU (High Intensity Focused Ultrasound) can be used for focal prostate cancer treatment โ but they differ in mechanism (cold vs heat), technical approach (transperineal probes vs transrectal ultrasound beam), and ice ball visibility. Cryoablation produces a directly visible ice ball on TRUS, enabling real-time treatment confirmation; HIFU ablation zones are not directly visible during treatment. Both have published focal treatment outcome data. The choice between them at most specialist centres is driven by institutional expertise, technology availability, and tumour location within the gland.
Can I have sex after focal prostate cryoablation?
In most cases, yes โ focal cryoablation specifically aims to preserve sexual function by sparing the contralateral neurovascular bundle. Published potency preservation rates after focal hemi-gland cryoablation are 50โ70% in men who were potent before treatment. The recovery of erectile function, if affected, typically occurs over 6โ18 months as nerve function returns. Ejaculatory function is also affected in the majority of patients โ retrograde ejaculation or absent ejaculation is common due to the freeze effect on the ejaculatory ducts, even with focal approaches. These aspects should be discussed in detail with the treating urologist before treatment.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Considering Cryoablation for Your Prostate Cancer?
CancerFax reviews your PSA, biopsy results, staging MRI, and risk category to assess whether whole-gland or focal cryoablation is appropriate โ and coordinates access at specialist prostate cryoablation centres in China and India.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified urologist before making prostate cancer treatment decisions.